Analytical Data
-
Gene name
KCNH8
- Application
-
Alternative Names
ELK1 Short name: hElk1 Ether-a-go-go-like potassium channel 3 Short name: ELK channel 3 Short name: ELK3 Voltage-gated potassium channel subunit Kv12.1
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q96L42
-
Expression Region
899-1107aa
-
Molecular Weight
26.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KCNH8, also known as potassium voltage-gated channel subfamily H member 8, is a member of the voltage-gated potassium channel family, which plays a crucial role in regulating neuronal excitability and cardiac functions. Research into KCNH8 has gained momentum due to its involvement in various physiological processes and potential implications in diseases. This channel is primarily expressed in the brain, where it contributes to setting the resting membrane potential and shaping action potentials. Dysregulation of KCNH8 has been implicated in several neurological disorders, including epilepsy and schizophrenia. Understanding the structure and function of KCNH8 through recombinant protein studies provides insights into its gating mechanisms, ion selectivity, and interaction with other cellular components. These investigations utilize techniques such as heterologous expression systems to produce functional KCNH8 proteins for electrophysiological analysis. The study of KCNH8's pharmacology is also of great interest, as it may reveal potential therapeutic targets for drug development. Overall, ongoing research into KCNH8 recombinant proteins aims to elucidate their roles in health and disease, offering promising avenues for therapeutic interventions in ion channel-related disorders.
